AstraZeneca to develop asthma treatment

As reported by PharmaTimes, AstraZeneca has signed an exclusive global licence deal with USA-based Rigel Pharmaceuticals for a potential new treatment for chronic asthma.

The drugs is Rigels R256, it is being investigated as a treatment for moderate to severe chronic asthma and in preclinical research has been shown to reduce airway inflammation and improve lung function.

AstraZeneca will be responsible for beginning first-in-human clinical studies for R256 and have exclusive rights to commercialise the drug around the world.  Rigel will receive an upfront fee of $1 million with an additional $8.25 million in early milestone payments. In total, the deal could be worth up to $100 million.

Mene Pangalos, head of innovative medicines at AstraZeneca, said “there remains a need for more targeted therapies for moderate to severe chronic asthma”.

Looking for a job in the Pharmaceutical Industry?Click here to search our pharmaceutical jobs online now.

Posted in: company news, News
CK Logo in place of featured image